Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Cell Therapeutics Says UW's Neuro-Oncology Program Begins Patient Enrolment

RELATED NEWS
Trade CTIC now with 

Cell Therapeutics, Inc. (CTIC: Quote) on Tuesday said the University of Washington's School of Medicine, Departments of Neurology and Neurosurgery, Division of Neuro-Oncology has begun enrolling patients in a randomized phase II clinical study comparing the combination of OPAXIO (paclitaxel poliglumex, PPX, CT-2103) and radiation therapy, or RT, to the combination of temozolomide, or TMZ, and RT for patients with newly-diagnosed glioblastoma multiforme.

The study objective is to determine whether paclitaxel poliglumex and RT are likely to improve progression-free survival and overall survival compared to TMZ and RT. It will also evaluate neuro-cognitive function and toxicities of these therapies.

Glioblastoma multiforme or GBM is a poor-prognosis high-grade malignant brain tumor with an active gene called MGMT, which substantially decreases the effectiveness of standard therapy with TMZ.

This study is a multicenter trial initiated and led by the Neuro-Oncology department of the Brown University Oncology Research Group in Providence, Rhode Island. The first patient at UW recently has been enrolled.

Click here to receive FREE breaking news email alerts for CTI BioPharma Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After moving mostly higher over the course of the previous week, stocks showed a notable move back to the downside during trading on Monday. With the drop on the day, the Dow pulled back well off last Friday's record closing high. After reporting four consecutive monthly increases, the National Association of Realtors released a report on Monday showing an unexpected drop in U.S. existing home sales in the month of August. NAR said existing home sales fell 1.8 percent to a seasonally adjusted annual rate of 5.05 million in August. The European Central Bank remains ready to use additional unconventional tools to counter risks to the inflation outlook and to boost the euro area economy, ECB President Mario Draghi said on Monday. "The Governing Council remains fully determined to counter risks to the medium-term outlook for inflation," Draghi said in Brussels.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.